Ga-68-PSMA PET/CT and PET/MRI in high-risk prostate cancer patients


Sanli Y., Sanli O., Simsek D. H. , Subramaniam R. M.

NUCLEAR MEDICINE COMMUNICATIONS, cilt.39, ss.871-880, 2018 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 39 Konu: 10
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1097/mnm.0000000000000888
  • Dergi Adı: NUCLEAR MEDICINE COMMUNICATIONS
  • Sayfa Sayıları: ss.871-880

Özet

Treatment of high-risk prostate cancer (HRPCa) is challenging. Local staging and metastatic evaluation are important for the patient management. Recently, prostate-specific membrane antigen (PSMA)-based imaging modalities such as PSMA PET/CT and PET/MRI have received significant attention for detection of recurrent prostate cancer sites with elevated prostate-specific antigen levels, after therapy. Current evidence suggests that these imaging modalities may also have a role for the management of patients with HRPCa. In this review, we discuss PSMA-based imaging modalities in the management of patients with HRPCa.